Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 212M 262M 228M 195M 368M 25.02B 373M 2.5B 981M 12.46B 984M 963M 41.77B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 240M 296M 258M 220M 416M 28.29B 422M 2.83B 1.11B 14.08B 1.11B 1.09B 47.22B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.02x
Free-Float
81.19%
Yield 2026 *
-
Yield 2027 * -
1 day-1.94%
1 week-4.97%
1 month-9.81%
3 months-16.71%
6 months+12.03%
Current year+12.38%
1 week 13.9
Extreme 13.9
15.74
1 month 13.9
Extreme 13.9
16.3
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
26.6
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap.
1/22/24 A Buy 30,228 0.2396%
7/6/23 A Buy 2,000 0.0016%
1/11/22 A Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%-4.97%-4.97%+64.84% 262M
+0.32%-0.66%+66.67%+22.08% 322B
+0.21%+2.87%+29.78%-10.42% 71.6B
-0.91%+0.74%+37.64%+92.13% 9.79B
-3.60%-2.43%-1.64%-5.95% 8.39B
+1.80%-1.99%-19.96%-2.95% 4.3B
-0.68%-1.87%-37.76%+5.72% 3.81B
+3.08%-1.41%-10.94%+5.60% 3.58B
-2.15%-3.40%+27.15%+45.42% 2.59B
+0.85%+9.88%-4.55%-6.36% 2.25B
Average -0.30%-0.80%+8.14%+21.01% 42.81B
Weighted average by Cap. +0.21%-0.10%+55.39%+17.18%

Financials

2026 *2027 *
Net sales 94.7M 117M 102M 86.95M 164M 11.17B 167M 1.12B 438M 5.56B 440M 430M 18.65B 116M 143M 124M 106M 200M 13.63B 203M 1.36B 535M 6.79B 536M 525M 22.76B
Net income - -
Net Debt 27.7M 34.23M 29.76M 25.43M 48.03M 3.27B 48.77M 327M 128M 1.63B 129M 126M 5.46B 21.4M 26.45M 22.99M 19.65M 37.1M 2.52B 37.68M 252M 99M 1.26B 99.33M 97.15M 4.21B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
31/07/26 CHF 14.16 -1.94% 75,092
30/07/26 CHF 14.44 +0.98% 72,246
29/07/26 CHF 14.30 -4.67% 177,104
28/07/26 CHF 15.00 -1.70% 62,611
27/07/26 CHF 15.26 +2.42% 65,713
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.16CHF
Average target price
27.50CHF
Spread / Average Target
+94.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock